Clinical Immuno-Oncology - E-Book

Know about the book -

Clinical Immuno-Oncology - E-Book is written by John E. Niederhuber and published by Elsevier Health Sciences. It's available with International Standard Book Number or ISBN identification 0323877648 (ISBN 10) and 9780323877640 (ISBN 13).

Offering focused, practical, and up-to-date content on immunotherapies used to treat a wide variety of cancer types, Clinical Immuno-Oncology covers the basic cellular and molecular mechanisms involved in cancer initiation and progression. The text reviews the development of tumor specific antigens and the challenges of developing cancer immunotherapies. Every effort is made to relate the fundamental aspects of host immunity to the efficacy of current immunotherapies and how they work in conjunction with the immune system to combat cancer. This foundational resource explains the basics of cancer immunotherapy, discusses best practices, and provides recommendations from experienced clinicians in the field. Dr. John E. Niederhuber and a team of expert contributing authors provide clinically focused information essential for integrating these new therapies into practice—making this an ideal resource for fellows, practitioners, and other cancer team members in medical oncology, radiation oncology, cancer surgery, immunology, and cancer research. - Offers balanced and synthesized content on clinical science, clinical and translational research, and evidence-based practice for cutting-edge immunotherapies. - Discusses clinical applications of immunotherapies in common types of cancer including melanoma, breast cancer, pancreatic cancer, colon and rectum cancer, prostate cancer, leukemias, and hematologic malignancies. - Includes dedicated chapters on immune responses, innate immunity, active immunization against cancer, and cell-based therapies by leading experts. - Covers key topics such as cancer immunotherapy in the presence of COVID-19, immunotherapeutics, new findings concerning the role of the microbiome in immunotherapy, advances in engineered cell-based therapies, and active immunization against cancer.